NO308539B1 - Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat - Google Patents

Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat Download PDF

Info

Publication number
NO308539B1
NO308539B1 NO922383A NO922383A NO308539B1 NO 308539 B1 NO308539 B1 NO 308539B1 NO 922383 A NO922383 A NO 922383A NO 922383 A NO922383 A NO 922383A NO 308539 B1 NO308539 B1 NO 308539B1
Authority
NO
Norway
Prior art keywords
antibody
ricin
target cell
residue
toxin
Prior art date
Application number
NO922383A
Other languages
English (en)
Norwegian (no)
Other versions
NO922383L (no
NO922383D0 (no
Inventor
Andrew Firman Wright
David Charles Blakey
John Edward Fitton
Leif Lindholm
Peter Lind
Jan Holmgren
Original Assignee
Zeneca Ltd
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, Kabi Pharmacia Ab filed Critical Zeneca Ltd
Publication of NO922383D0 publication Critical patent/NO922383D0/no
Publication of NO922383L publication Critical patent/NO922383L/no
Publication of NO308539B1 publication Critical patent/NO308539B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO922383A 1991-07-03 1992-06-17 Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat NO308539B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (3)

Publication Number Publication Date
NO922383D0 NO922383D0 (no) 1992-06-17
NO922383L NO922383L (no) 1993-01-04
NO308539B1 true NO308539B1 (no) 2000-09-25

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922383A NO308539B1 (no) 1991-07-03 1992-06-17 Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat

Country Status (24)

Country Link
EP (1) EP0528527B1 (zh)
JP (1) JP3735379B2 (zh)
KR (1) KR100252147B1 (zh)
AT (1) ATE164768T1 (zh)
AU (1) AU665546B2 (zh)
CA (1) CA2073113C (zh)
CZ (1) CZ209792A3 (zh)
DE (1) DE69225035T2 (zh)
DK (1) DK0528527T3 (zh)
ES (1) ES2113923T3 (zh)
FI (1) FI106928B (zh)
GB (2) GB9114399D0 (zh)
GR (1) GR3026575T3 (zh)
HU (1) HU215243B (zh)
IE (1) IE922190A1 (zh)
IL (1) IL102399A (zh)
MY (1) MY110513A (zh)
NO (1) NO308539B1 (zh)
NZ (1) NZ243437A (zh)
PT (1) PT100660B (zh)
SK (1) SK209792A3 (zh)
TW (1) TW329425B (zh)
ZA (1) ZA924973B (zh)
ZW (1) ZW10192A1 (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
EP0610179B1 (en) * 1990-07-20 1996-10-16 Pharmacia AB (reg.number 556131-9608) Target specific antibody-superantigen conjugates and their preparation

Also Published As

Publication number Publication date
ZA924973B (en) 1993-04-28
NZ243437A (en) 1994-10-26
NO922383L (no) 1993-01-04
CA2073113C (en) 2004-09-14
GB9212880D0 (en) 1992-07-29
DE69225035T2 (de) 1998-08-13
GB9114399D0 (en) 1991-08-21
GR3026575T3 (en) 1998-07-31
ES2113923T3 (es) 1998-05-16
SK209792A3 (en) 1994-06-08
IL102399A0 (en) 1993-01-14
FI923085A0 (fi) 1992-07-03
HUT67048A (en) 1995-01-30
TW329425B (en) 1998-04-11
JPH05320065A (ja) 1993-12-03
CZ209792A3 (en) 1993-01-13
IL102399A (en) 2003-05-29
EP0528527A2 (en) 1993-02-24
MY110513A (en) 1998-07-31
ATE164768T1 (de) 1998-04-15
CA2073113A1 (en) 1993-01-04
PT100660B (pt) 1999-06-30
EP0528527B1 (en) 1998-04-08
EP0528527A3 (en) 1993-03-17
ZW10192A1 (en) 1993-03-31
PT100660A (pt) 1993-10-29
JP3735379B2 (ja) 2006-01-18
FI106928B (fi) 2001-05-15
DE69225035D1 (de) 1998-05-14
AU665546B2 (en) 1996-01-11
NO922383D0 (no) 1992-06-17
DK0528527T3 (da) 1999-01-18
HU9202219D0 (en) 1992-10-28
KR930001928A (ko) 1993-02-22
HU215243B (hu) 1998-11-30
KR100252147B1 (ko) 2000-09-01
FI923085A (fi) 1993-01-04
AU1943092A (en) 1993-01-07
IE922190A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
US5840840A (en) Selective RNase cytotoxic reagents
US10875925B2 (en) Anti-CD123 antibodies and conjugates and derivatives thereof
EP0170697B1 (en) Toxin conjugates
US11679162B2 (en) Anti-5T4 antibody-drug conjugate and use thereof
ES2214494T3 (es) Estructuras de fijacion dirigidas contra el antigeno ca55.1.
JP2008520186A (ja) 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
JPS61501449A (ja) 毒素複合体
EP2917243B1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
NO321548B1 (no) Monoklonalt antistoff som binder seg til GA733-1-antigen, hybridom, konjugat, humant/muse-rekombinant antistoff, nukleinsyremolekyl, plasmid, vertsvektorsystem samt fremgangsmate for fremstilling av et protein.
JP6537970B2 (ja) Ｈｅｒ３のベータヘアピン及びｈｅｒ４のベータヘアピンに結合する抗ｈｅｒ３／ｈｅｒ４抗原結合タンパク質
WO2022001864A1 (zh) 一种抗体-药物偶联物，其制备方法及应用
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
JPH09509043A (ja) 植物ブリオニア・ディオイカから単離された新規なリボソーム不活性化タンパク質
WO1992015327A1 (en) Recombinant double chain immunotoxins
TW201605902A (zh) 結合ＨＥＲ３之β－髮夾結構的抗ＨＥＲ３抗體
EP0739984A1 (en) Bivalent polypeptides containing at least two domains
CN115210262B (zh) 人源化抗-cd22重组免疫毒素及其应用
NO308539B1 (no) Konjugat, anvendelse av konjugat, samt farmasøytisk blanding som omfatter et konjugat
JPS62232387A (ja) 組換リシントキシン
US11020490B2 (en) Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit

Legal Events

Date Code Title Description
MK1K Patent expired